Seamless Therapeutics CEO Anne-Kristin Heninger and CSO Felix Lansing

Ger­man biotech launch­es with ‘seam­less’ gene edit­ing plat­form built on evolv­ing en­zymes

Seam­less Ther­a­peu­tics has launched with €11.8 mil­lion (rough­ly $12.5 mil­lion) in seed fund­ing to build out a gene edit­ing plat­form.

As more and more gene …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.